Chinese pharma groups partner in $150M licensing deal; Pfizer to join lawsuit on tariffs
Chinese pharma group Alphamab Oncology announced yesterday that its subsidiary signed a contract worth potentially as much as $150 million with JMT-Bio, a subsidiary of CSPC Pharmaceutical Group, to develop and commercialize an anti-HER2 bispecific antibody KN026 in China.
JMT will bear the costs of all clinical trials involving KN026 in Mainland China in exchange for exclusive licensing rights of KN026 on indications of breast cancer and gastric or gastroesophageal junction cancers. In addition, Jiangsu and JMT will collaborate on developing more potential indications of KN026.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.